Warowicka Alicja, Qasem Badr, Dera-Szymanowska Anna, Wołuń-Cholewa Maria, Florczak Patryk, Horst Nikodem, Napierała Marta, Szymanowski Krzysztof, Popenda Łukasz, Bartkowiak Grażyna, Florek Ewa, Goździcka-Józefiak Anna, Młynarz Piotr
Department of Animal Physiology and Development, Faculty of Biology, Adam Mickiewicz University in Poznań, 61614 Poznań, Poland.
NanoBioMedical Centre, Adam Mickiewicz University in Poznań, 61614 Poznań, Poland.
Pharmaceutics. 2021 Jun 23;13(7):931. doi: 10.3390/pharmaceutics13070931.
Endometriosis is a gynecological disease defined by the presence of endometrial tissue outside the uterus. To date, the effective treatment of this disease is still based on invasive surgery or laparoscopy. L. (Papaveraceae) belongs to medicinal, latex-bearing plants. Extracts from the plant are a rich source of pharmacologically active agents. Protoberberine compounds derived from possess anticancer and antiproliferative activities. In the present study of a rat model of endometriosis, we investigated the influence of the plant protoberberine-rich fraction (BBR) obtained from the medicinal plant on the development of endometriosis. To understand of BBR therapeutic potential for endometriosis, metabolomics has been applied to study. BBR was prepared from an ethanolic extract of dry plants . Rats ( = 16) with confirmed endometriosis were treated with BBR administered orally (1 g/kg) for 14 days. Blood serum samples were collected from all of the animals and metabolites were studied using the NMR method. The metabolomic pattern was compared before and after the protoberberine treatment. The performed analysis showed significant changes in the concentrations of metabolites that are involved in energy homeostasis, including glucose, glutamine, and lactate. Histopathological studies showed no recurrence of endometriosis loci after treatment with BBR. The results of the study found that BBR treatment prevents the recurrence of endometriosis in rats. Moreover, metabolomics profiling can be applied to better understand the mechanisms of action of these protoberberine secondary plant metabolites. Our findings provide new insights into the pharmaceutical activity of natural protoberberine plant compounds.
子宫内膜异位症是一种妇科疾病，其定义为子宫外存在子宫内膜组织。迄今为止，这种疾病的有效治疗仍基于侵入性手术或腹腔镜检查。博落回属罂粟科药用、含乳胶植物。该植物提取物富含药理活性剂。从博落回中提取的原小檗碱化合物具有抗癌和抗增殖活性。在本项针对子宫内膜异位症大鼠模型的研究中，我们研究了从药用植物博落回中提取的富含原小檗碱的组分（BBR）对子宫内膜异位症发展的影响。为了解BBR对子宫内膜异位症的治疗潜力，已应用代谢组学进行研究。BBR由干燥植物博落回的乙醇提取物制备而成。对确诊为子宫内膜异位症的16只大鼠口服给予BBR（1 g/kg），持续14天。从所有动物采集血清样本，并使用核磁共振方法研究代谢物。比较原小檗碱治疗前后的代谢组学模式。所进行的分析表明，参与能量稳态的代谢物浓度发生了显著变化，包括葡萄糖、谷氨酰胺和乳酸。组织病理学研究表明，BBR治疗后子宫内膜异位症病灶未复发。研究结果发现，BBR治疗可预防大鼠子宫内膜异位症的复发。此外，代谢组学分析可用于更好地理解这些原小檗碱次生植物代谢物的作用机制。我们的研究结果为天然原小檗碱植物化合物的药理活性提供了新的见解。
